

## **BOARD OF DIRECTORS**

### **David Macfarlane (69), Non-executive Chairman**

David was previously a partner at two of the City's most prominent law firms, Stephenson Harwood and Ashurst. David advised a number of high profile companies, banks and other institutions on activities including M&A and capital raising. Whilst at Ashurst LLP, he became involved in management and was head of its corporate department until his retirement in 2002. David is currently Chairman of JZ Capital Partners, the quoted investment company and has previously held the position of Non-Executive Director at several companies including Platinum Investment Trust, Allied Healthcare, Turftrax, Mancal Energy UK and Prospekt Medical

*The Chairman is primarily responsible for the efficient functioning of the Board. He ensures that all Directors receive sufficient relevant information on financial, business and corporate issues prior to meetings. Any specific actions arising during meetings are agreed by the Board and a comprehensive follow-up procedure ensures their completion. The Chief Executive's responsibilities focus on coordinating the Group's business and implementing Group strategy. Regular interaction between the Chairman and Chief Executive between meetings ensures the Board remains fully informed of developments in the business at all times*

### **Executive Directors**

#### **Crispin Simon (57), Chief Executive Officer**

Crispin Simon has a 25-year track record in industry, predominantly in the commercialisation of Medical Technology products.

Following a career which included NM Rothschild, McKinsey, Rexam and Smith & Nephew, where he was latterly President of the Endoscopy Division, Crispin was Chief Executive of Biocompatibles International Plc ("Biocompatibles") until its sale to BTG Plc in early 2011. At Biocompatibles, he led a team that developed three medical products businesses: the Cardiovascular Stent business, sold to Abbott Laboratories Inc for £145 million; the Contact Lens business, sold to Cooper Industries Inc for £80 million and the Drug-eluting Bead business, which was sold as part of the disposal of the whole company to BTG for £165 million. In addition, £123 million cash was returned to shareholders.

From 2012 to October 2014, Crispin was a full time Director in the UK Government's Department of Business, Innovation and Skills. He is a Non-Executive Director of the NHS Trust Development Authority and a trustee of Alive and Kicking, an African social enterprise.

### Peter Worrall (62), Chief Financial Officer

Peter was previously Chief Executive of Pharminox Limited, a company focused on the discovery and development of drugs to treat cancer. Peter was formerly Corporate Development Director of Vernalis plc, a company formed from the merger of British Biotech plc and Vernalis Group plc (formerly Vanguard Medical Group plc). He joined Vanguard as Chief Financial Officer in 1993 as a venture capital backed start-up company, and saw it through a number of private and public funding rounds, including its IPO on the Main Market of the London Stock Exchange in May 1996, as well as the acquisition of Cerebrus Ltd in late 1999. He became acting Chief Executive in early 2003, and led the merger discussions with British Biotech later that year.

In 1981 he joined Imed Ltd, a manufacturer of intravenous infusion pumps, initially as Financial Controller, becoming Finance Director and subsequently General Manager. In 1988 he established his own company, Isys Medical Ltd, as the vehicle for a management buy-out of Imed's UK manufacturing and R&D operations and ran Isys for three years before selling out to Danby Medical Ltd, a venture capital backed infusion pump company, which he joined as Finance Director. Danby was sold to Baxter Healthcare in 1993.

Peter received a Masters degree in economics from the University of St Andrews in 1977, and qualified as a chartered accountant with Arthur Andersen & Co in 1980.

### Richard Little (49), Chief Technology Officer and Co-founder of RBL

Richard formed Rex Bionics Ltd in 2007 with fellow engineer Robert Irving to develop innovative medical robotic technology that could bring new-found mobility to many thousands of users worldwide. With an extensive career including marine engineering, research and development, contract programme management and information technology, Richard has held senior leadership roles in medical technology, automotive and military industries. These include a programme management role for Navman, finance manager for BAE Systems and Group Technical Director for Taisun (CIMC Raffles), based in Singapore, responsible for transitioning four manufacturing companies to Asia and the technical leadership for the group.

### Non-Executive Directors

Jeremy Curnock Cook (65), Deputy Chairman

Jeremy was formerly managing director of the Rothschild Bioscience Unit, then one of the U.K.'s largest and most established biotechnology investment

managers, where he was responsible for managing over \$1bn invested in more than 160 companies. While at Rothschild, he was responsible for the conception and launch of the International Biotechnology Trust (IBT), as well as the first dedicated biotechnology fund for the Australian market, and a joint venture with Johnson & Johnson Development Corporation for the creation of Healthcare Ventures, an investment vehicle dedicated to seed stage investments in Europe. Prior to joining Rothschild, Jeremy founded the International Biochemicals Group (IBG) in 1975, subsequently building an 80-person company focused on the development and commercialisation of products containing tailored microbial strains for application in industrial pollution control and agriculture. IBG's clients included multinationals such as McDonalds and Royal Dutch Shell and it was successfully sold to Royal Dutch Shell in 1985. Jeremy has served on more than 30 boards of directors in the healthcare and medical sciences sector in the UK, Europe, USA, Canada, Japan and Australia. He was previously chair of Biocompatibles International Ltd and is chair of AmpliPhi Biosciences Corporation.

As the managing director of Bioscience Managers, Jeremy is responsible for the IB Australian Bioscience Fund I as well as the Asia Pacific Healthcare Fund. Jeremy received his MA in Natural Sciences from Trinity College in Dublin in 1971, and was a research scientist at the Institute of Cancer Research from 1972 to 1973.

#### Dr William Hunter (53), Non-Executive Director

Bill is currently the Interim President, Director and CEO of Cardiome Pharma Corporation, a commercial-stage NASDAQ and TSE listed healthcare company with an approved drug treatment (BRINAVESS™) for atrial fibrillation.

Prior to Cardiome, Bill co-founded Angiotech Pharmaceuticals in 1992 and was Chief Executive Officer in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through three rounds of private equity financing, its IPO and listing on the Toronto Stock Exchange and NASDAQ, totalling over \$1B in equity and debt financings, a debt restructuring and eight separate corporate acquisitions. During that time, Angiotech grew to become a profitable, diversified, healthcare company with over 1,400 employees, several thousand commercially available products, 12 facilities in five countries and worldwide annual revenues exceeding US\$250m. Bill currently also serves as a director of Zalicus Inc (NASDAQ: ZLCS) and has served previously on the boards of Aspreva Pharmaceuticals, Anormed Pharmaceuticals, Active Pass Pharmaceuticals, Neuromed Pharmaceuticals and Angiotech Pharmaceuticals.

### Victoria Provis (59), Non-Executive director

Victoria Provis has over 30 years' experience in the corporate communications, strategic consulting and human resources sectors. Victoria spent her early career in corporate communications, working with firms such as KPMG, Burson Marsteller and McKinsey & Company, before moving into the world of executive search in 1993. From 1995 to 2011, Victoria was a Partner with leading UK search firm Odgers Berndtson in London, building its specialist corporate communications practice as well as handling non-executive director appointments across a wide range of businesses. Victoria also opened and chaired the firm's Cardiff office from 2005.

Victoria now holds a portfolio of non-executive appointments. Since 2008, she has been a Trustee of Amgueddfa Cymru/National Museum Wales, where she chairs the Development Board and also sits on the Appointments and Remuneration Committee. Victoria was appointed by the Welsh Government to be a member of the Wales Tourism Advisory Board with effect from January 2014. From 2007-15 she was also a member of Glas Cymru/Welsh Water. She sits on the Advisory Council of UWC Atlantic College, where she was Vice Chair of the Governing

Board from 2002-8. Victoria received an MBA from INSEAD, Europe's leading business school, in 1984 and a BA (Hons) in Economics from the University of British Columbia in 1976.

### John Roden Plimmer (59), Non-Executive Director

John is a New Zealand citizen, resident in London, UK. He is a private equity investor and former corporate finance adviser. His main business interests today involve direct investing in and advising start-up and early-stage businesses.

From 1981 to 1998, John Plimmer had an extensive career in Corporate Finance with the Hambros Bank Group in Melbourne, Sydney and London. In 1995, he was appointed a Director of the Board of Hambros Bank Limited in London.

From 1998 to 2012, he was the Managing Director JZ International (JZI), the London based European affiliate of The Jordan Company, a US\$6 billion private equity partnership. At JZI, he established the executive team and implemented the investment strategy; this entailed: investing, managing and realising a portfolio of private SME investments across a range of industry sectors in the UK, The Netherlands, Nordic countries, Italy and Spain.

John graduated in 1981 from Victoria University of Wellington, NZ with a Bachelor of Commerce and Administration (Economics).

**Joseph A. Cucolo (56), Non-Executive Director**

Joe is a US citizen and lives in upstate New York. Before joining Rex he had a long and successful career with Zimmer Holdings Inc., one of the largest medical device companies in the world, latterly as President of Americas with responsibility for a \$2.5 billion business covering the United States, Canada and Latin America. He left Zimmer in 2015 to pursue new business interests following Zimmer's acquisition of its major competitor, Biomet.

Earlier in his career, Joe was the sole owner and President of Zimmer New England, an independent distributorship in the northeast region of the United States.